达托霉素治疗菌血症及感染性心内膜炎的研究进展  

Progress in the Treatment of Bacteremia and Infective Endocarditis by Daptomycin

作　　者：徐业成[1] 苗丽[1] 雷小红[1] 邓万俊[1] 

机构地区：[1]南华大学附属南华医院,湖南衡阳421002

出　　处：《国外医药（抗生素分册）》2007年第5期219-224,共6页World Notes on Antibiotics

摘　　要：达托霉素(daptomycin)是获准上市的首个环脂肽类抗生素。其结构新颖,杀菌机制独特。体外试验证实其对多重耐药革兰阳性细菌有快速有效的浓度依赖性杀菌作用,已被批准治疗革兰阳性细菌引起的皮肤与皮肤组织感染、金葡菌性菌血症或右侧心内膜炎。达托霉素6mg/(kg·d),iv治疗对甲氧西林敏感的金葡菌(MSSA)或耐甲氧西林金葡菌(MRSA)性菌血症及右侧心内膜炎的疗效不亚于传统疗法,安全性及耐受性好。Daptomycin is the first approved member of a new class of antibiotics, lipopeptides which has a specific structure and an unusual mechanism of action. The studies in vitro indicated that daptomycin is a potent and concentration-dependant bactericidal against a broad range of multidrug-resistant gram-positive pathogens. It was approved for the treatment of complicated skin and skin-structure infections caused by gram-positive microorganisms, as well as the treatment of bacteremia and right-sided endocarditis caused by Staphylococcus aureus. The efficacy of daptomycin at a once-daily dose of 6mg/kg is comparable to the standard therapy for the treatment of bacteremia and right-sided endocarditis caused by methicillin sensitive Saphylococcus aureus （MSSA） or methicillin resistant Staphylococcus aureus （MRSA）. It is also considered as a relatively safe and tolerable agent.

关 键 词：达托霉素 菌血症 心内膜炎 葡萄球菌 

分 类 号：R978.19[医药卫生—药品] R969.4[医药卫生—药学]